BTIG Starts Epirus Biopharmaceuticals (EPRS) at Buy

BTIG initiated coverage on EPIRUS Biopharmaceuticals (NASDAQ: EPRS) with a Buy rating and a price target of $15. Analyst Hartaj Singh warned investors not to miss the "biosimilar tidal wave."

"Pure-play biosimilar drug development companies are few and far between, due to the perceived competitive intensity in this arena from much larger players. Our optimism on Epirus is based on our belief that winners in the biosimilar arena will be companies with a ‘boots on the ground’ local market strategy. Since biosimilar drug development is already low risk in markets like the EU, the commercialization roll-out will separate the winners from the rest. We are bullish on Eprius’ strategy," said Sign.

For an analyst ratings summary and ratings history on EPIRUS Biopharmaceuticals click here. For more ratings news on EPIRUS Biopharmaceuticals click here.

Shares of EPIRUS Biopharmaceuticals closed at $5.51 yesterday.

You May Also Be Interested In

• Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
• Goldman Sachs Resumes Dada Nexus Ltd. (DADA) at Neutral
• Scotiabank Starts Tenable (TENB) at Sector Perform